Gritstone Bio is experiencing a decline in its stock value due to various challenges it is currently facing. These challenges include a significant workforce reduction of 40% following delays in the CORAL Phase 2b study and a setback in funding. The company did not receive expected external funding due to the study delay, which has impacted its workforce. Despite these obstacles, Gritstone is staying dedicated to its core programs, with the upcoming release of GRANITE data expected later this quarter.
Recently, Gritstone was awarded a contract by BARDA to conduct a Phase 2b study on its self-amplifying mRNA vaccine candidate for COVID-19. However, this study has faced delays and funding issues. Despite these setbacks, Gritstone’s core programs and milestones remain unchanged, with continued progress in cancer vaccines and other therapeutic areas.
GRTS Stock Price Drops 27.86% on March 2, 2024: What Investors Need to Know
On March 2, 2024, GRTS stock experienced a significant drop in price, closing at $2.02, which was a $0.78 decrease from the previous market close. This represents a 27.86% drop in the stock price. However, after-hours trading saw a slight increase in the stock price, with GRTS rising by $0.06.
Despite the drop in price on March 2, GRTS is still trading in the middle of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been relatively stable over the long term.
Investors may be wondering what caused the sudden drop in GRTS stock price on March 2. It is important to consider factors such as market conditions, company performance, and industry trends when analyzing stock performance. After-hours trading can sometimes be volatile and may not always accurately reflect the overall market sentiment.
As with any investment, it is important for investors to conduct thorough research and consider their risk tolerance before making any decisions. While the drop in GRTS stock price on March 2 may be concerning to some investors, it is important to look at the bigger picture and consider the stock’s overall performance and potential for future growth.
GRTS Stock Declines in Financial Performance in 2024: Revenue and Net Income Drop Significantly
On March 2, 2024, GRTS stock experienced a decline in its financial performance compared to the previous year and the last quarter. According to data from CNN Money, the company reported a total revenue of $9.27 million over the past year, which represents an 80.16% decrease from the previous year. In the last quarter, GRTS generated $361,000 in total revenue, marking a 9.75% decrease from the previous quarter.
Furthermore, GRTS reported a net income of -$119.69 million over the past year, reflecting a 59.41% decrease from the previous year. In the last quarter, the company’s net income was -$38.43 million, showing a 9.01% decrease from the previous quarter.
Additionally, GRTS reported an earnings per share (EPS) of -$1.32 over the past year, which is a 38.31% decrease from the previous year. In the last quarter, the company’s EPS was -$0.33, indicating an 8.6% decrease from the previous quarter.
